Browse the evidence

Poor fetal and infant nutrition (low birth weight) increases the risk of developing Type 2 diabetes in adulthood, likely through programmed insulin resistance and beta-cell dysfunction.

For expectant mothers, maintaining good nutrition and managing blood sugar (if diabetic) is important for the child's long-term metabolic health. For adults with low birth weight, being aware of the increased risk for insulin resistance is prudent.

Decreasing TOR pathway signaling in yeast extends chronological life span by inducing a starvation response that increases stress resistance and storage carbohydrate accumulation.

This research in yeast suggests that limiting nutrient availability, specifically amino acids, triggers a survival mechanism (reduced TOR signaling) that extends life by boosting stress resistance. While this is a model organism study, it supports the human health principle that calorie restriction or specific nutrient limitations may promote longevity through conserved biological pathways.

Homozygosity for the minor G allele of the FOXO3A gene (rs2802292) is strongly associated with increased human longevity, conferring approximately twice the protective effect (OR 2.75) compared to the major TT allele.

You cannot change your FOXO3A genotype, but this research highlights that the genetic variants associated with longevity are also linked to better insulin sensitivity and lower risk of chronic diseases like heart disease and cancer. Focus on maintaining high insulin sensitivity through diet and exercise, as this may mimic the metabolic profile associated with the 'longevity genotype' (lower fasting insulin, lower HOMA-IR).

Testosterone replacement therapy has no significant effect on memory, cognitive function, or prostate-specific antigen (PSA) levels in older hypogonadal men over 12 months.

Based on this study, testosterone therapy did not improve memory or cognitive function, nor did it significantly change PSA levels in men without existing prostate disease. Do not expect cognitive benefits from this treatment.

Acromegaly, characterized by excess GH and IGF-I, leads to high bone turnover which can result in bone loss and vertebral fractures, particularly in patients with coexisting hypogonadism.

This paper describes a pathological condition (acromegaly) rather than a fitness intervention. If you have symptoms of acromegaly (excessive growth, jaw/hand changes), seek medical evaluation as it can negatively impact bone health.

Systemic administration of angiogenesis inhibitors (TNP-470, angiostatin, endostatin, Bay-129566, thalidomide) reduces adipose tissue mass and body weight in obese mice by inducing endothelial apoptosis and inhibiting endothelial proliferation, independent of direct adipocyte toxicity.

This research suggests that targeting the blood vessels within fat tissue (angiogenesis) can reduce fat mass. In obese mice, drugs that inhibit blood vessel growth (like TNP-470, angiostatin, endostatin) led to significant weight loss and fat reduction, comparable to leptin treatment. The weight loss was not just due to eating less, as treated mice lost more weight than control mice fed the same amount of food. This indicates a direct effect on fat tissue metabolism or structure. However, these are experimental drugs in mice, not approved human weight loss treatments.

FoxO transcription factors promote muscle atrophy by upregulating ubiquitin ligases (atrogin-1/MAFbx and MuRF1) and autophagy genes.

FoxO factors are responsible for breaking down muscle protein. They are inhibited by the IGF1-Akt pathway (activated by training). When Akt is low (e.g., during inactivity or starvation), FoxO is active, leading to muscle loss. To prevent this, maintain resistance training and adequate protein intake.

Hepatocellular carcinoma can develop in patients with nonalcoholic fatty liver disease (NAFLD) even in the absence of cirrhosis, often presenting with larger tumors and poorer prognosis due to lack of surveillance.

If you have fatty liver disease, be aware that liver cancer can develop even without advanced scarring (cirrhosis). Because these cases are often not detected early, it is important to discuss screening options with your doctor, especially if you have other metabolic risk factors like diabetes or obesity.

Maternal consumption of a high-fat diet during gestation and lactation causes hypothalamic inflammation and altered neural projections in offspring, predisposing them to obesity and metabolic disorders.

For expectant mothers, avoiding high-fat diets during pregnancy and breastfeeding may help prevent metabolic programming issues in the child, such as altered brain circuits that regulate hunger.

Pharmacological activation of AMP-activated protein kinase (AMPK) in the hypothalamus directly stimulates food intake in rodents.

This study identifies AMPK in the hypothalamus as a key driver of hunger. While this is a rodent study using direct brain injections, it suggests that metabolic states which activate AMPK (like low energy availability) signal the brain to increase food intake. For humans, this implies that extreme caloric restriction or metabolic stress might trigger biological hunger responses via this pathway, potentially making long-term adherence difficult.

PPARγ2, but not PPARγ1, plays the key role in adipogenic differentiation, as evidenced by the failure of cells with reduced PPARγ2 to differentiate and the inability of PPARγ1 to restore it.

Not all forms of PPARγ are equal. The specific PPARγ2 isoform is the critical driver of fat cell formation, which has implications for drug design targeting this specific pathway.

Several factors, including KLF2, GATA2/3, Pref-1, TAZ, and SIRT1, negatively regulate adipogenesis by inhibiting PPARγ and C/EBPα expression, thereby preventing the formation of mature adipocytes.

The body has natural 'brakes' on fat cell formation (like Pref-1 and SIRT1). Understanding these can lead to therapies that enhance these brakes to prevent obesity.

Genetic deficiency or pharmacological inhibition of the NLRP3 inflammasome (specifically Nlrp3, ASC, or Caspase-1) protects against high-fat diet-induced obesity and insulin resistance by reducing adipose tissue inflammation, lowering pro-inflammatory cytokines (IL-1β, IL-18), and increasing energy expenditure.

This research suggests that chronic low-grade inflammation in fat tissue, driven by the NLRP3 inflammasome, plays a key role in obesity and insulin resistance. While this is an animal study, it implies that targeting inflammatory pathways (like IL-1β) might help treat obesity and diabetes, independent of just reducing calorie intake. It highlights that obesity is an active inflammatory disease, not just a storage issue.

Inhibition of Errα using the synthetic inverse agonist XCT790 reduces PGC-1α-mediated cellular respiration and OXPHOS gene expression in muscle cells.

This study uses a specific drug (XCT790) to block Errα, proving that Errα is necessary for mitochondrial energy production. This supports the hypothesis that activating Errα (rather than blocking it) could be a therapeutic strategy for diabetes.

In Type 1 Diabetes, hyperglucagonemia (excess glucagon) is the primary cause of hyperglycemia and catabolic symptoms, rather than insulin deficiency alone.

For Type 1 Diabetics, managing blood sugar requires addressing high glucagon levels, not just injecting more insulin. Current insulin monotherapy often fails to suppress glucagon without causing hypoglycemia elsewhere. Therapies that suppress glucagon (like somatostatin analogs or leptin) may offer better stability than insulin alone.

Intermittent administration of senolytic drugs (Dasatinib + Quercetin) or genetic clearance of senescent cells alleviates obesity-induced metabolic dysfunction, including insulin resistance and glucose intolerance, in obese mice.

This research suggests that targeting senescent cells (cells that have stopped dividing and secrete inflammatory factors) using specific drug combinations (like Dasatinib and Quercetin) or genetic methods can improve metabolic health in obesity. While not yet a standard human treatment, it highlights senolytics as a potential future therapy for obesity-related diabetes and inflammation.

Prenatal exposure to severe famine during early gestation (conception to ~10 weeks) causes persistent, intermediate-level DNA methylation changes at specific regulatory regions (P-DMRs) that are associated with adverse metabolic phenotypes (higher LDL cholesterol) and growth outcomes (birth weight) in later life.

If you were exposed to severe nutritional deprivation during the first 10 weeks of pregnancy, you may have a higher risk of elevated LDL cholesterol and altered metabolic regulation due to persistent changes in your DNA methylation patterns. This does not mean you are destined for poor health, but it does suggest that monitoring your lipid profile and metabolic health is crucial. The study highlights specific genes (INSR, CPT1A) involved in insulin signaling and fatty acid oxidation, suggesting that lifestyle interventions focusing on metabolic health (diet, exercise) may be particularly important for this population to counteract these early-life epigenetic marks.

Exposure to the environmental contaminant tributyltin chloride (TBT) acts as a potent inducer of adipogenesis in vertebrates by functioning as a dual nanomolar-affinity ligand for retinoid X receptor (RXR) and peroxisome proliferator-activated receptor gamma (PPARγ), leading to increased lipid accumulation and adipose mass.

This research identifies a specific environmental chemical, tributyltin chloride (TBT), as a direct cause of increased fat mass in vertebrates. TBT acts by hijacking key fat-regulating receptors (RXR and PPARγ). While this does not provide a direct lifestyle intervention, it highlights that reducing exposure to organotin contaminants (found in some seafood, plastics, and treated materials) may be a relevant factor in obesity prevention strategies alongside diet and exercise.

Reduced sensitivity to light due to lens yellowing and reduced SCN neuronal coupling contributes to the desynchronization of peripheral clocks and weakened circadian output in older adults.

Your eyes let in less blue light as you age, weakening your body's time signal. Maximizing morning outdoor light exposure can help compensate for this reduced sensitivity and strengthen your circadian rhythm.

High-level gastrointestinal expression of bacterial bile salt hydrolase (BSH) enzymes significantly reduces host weight gain, plasma cholesterol, and liver triglycerides in mice.

This research suggests that increasing the activity of bile salt hydrolase (BSH) in the gut, potentially through specific probiotic bacteria (like certain Lactobacillus strains), may help reduce weight gain and lower cholesterol. While this is a mouse study, it highlights the gut microbiome as a target for metabolic health. You might explore probiotics known for BSH activity, but consult a doctor before making changes, especially if you have existing metabolic conditions.

Rimonabant, a CB1 receptor antagonist, was withdrawn due to an increased risk of serious psychiatric adverse events, including depression and suicidal ideation.

Rimonabant was withdrawn from the market because it significantly increased the risk of depression and suicidal thoughts compared to placebo.

Overexpression of the SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth in vivo by directly deacetylating and inhibiting the transcriptional activity of beta-catenin.

This research suggests that the biological pathway involving SIRT1 may help protect against colon cancer by turning off a key driver of tumor growth (beta-catenin). While this paper uses genetic overexpression in mice, it supports the idea that maintaining healthy SIRT1 function (potentially through calorie restriction or other means) might be beneficial for cancer prevention. It does not recommend specific supplements or doses for humans.

Islet amyloid polypeptide (IAPP) aggregation into small soluble oligomers causes beta-cell death via membrane disruption and oxidative stress, contributing to the loss of beta-cell mass in type 2 diabetes.

This research highlights that beta-cell failure in type 2 diabetes is actively driven by toxic protein aggregates (IAPP), not just passive aging. This suggests that therapies targeting amyloid formation (like pramlintide analogs or small molecule inhibitors) could preserve remaining beta-cell function, offering a pathway to slow disease progression beyond just lowering blood sugar.

Small, soluble IAPP oligomers (prefibrillar assemblies) are the primary cytotoxic species responsible for beta-cell death, whereas mature amyloid fibrils are less cytotoxic.

Therapies should target the early formation of soluble IAPP aggregates, not just the mature amyloid deposits, as the early aggregates are the primary cause of cell death.